A20 cells

A20 cells, also called ATCC TIB-208, is a cell line originally derived from B-cell lymphoma in an old BALB/c mouse.[1] A20 cells are used in medical research such as drug screening or vaccine target selection.[2][3][4]

References

Kim, KJ; Kanellopoulos-Langevin, C; Merwin, RM; Sachs, DH; Asofsky, R (1979). "Establishment and characterization of BALB/c lymphoma lines with B cell properties". Journal of Immunology. 122 (2): 549–554. PMID 310843.
Meziane el, K; Bhattacharyya, T; Armstrong, AC; Qian, C; Hawkins, RE; Stern, PL; Dermime, S (2004-10-10). "Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma". International Journal of Cancer. 111 (6): 910–920. doi:10.1002/ijc.20332. PMID 15300803.
Siegel, S; Wagner, A; Kabelitz, D; Marget, M; Coggin J, Jr; Barsoum, A; Rohrer, J; Schmitz, N; Zeis, M (2003-12-15). "Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies". Blood. 102 (13): 4416–23. doi:10.1182/blood-2003-01-0198. PMID 12869512. S2CID 9814435.
Siegel, S; Wagner, A; Schmitz, N; Zeis, M (2003). "Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model". British Journal of Haematology. 122 (6): 911–4. doi:10.1046/j.1365-2141.2003.04535.x. PMID 12956760.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kim, KJ; Kanellopoulos-Langevin, C; Merwin, RM; Sachs, DH; Asofsky, R (1979). "Establishment and characterization of BALB/c lymphoma lines with B cell properties". Journal of Immunology. 122 (2): 549–554. PMID 310843.

[2] Meziane el, K; Bhattacharyya, T; Armstrong, AC; Qian, C; Hawkins, RE; Stern, PL; Dermime, S (2004-10-10). "Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma". International Journal of Cancer. 111 (6): 910–920. doi:10.1002/ijc.20332. PMID 15300803.

[3] Siegel, S; Wagner, A; Kabelitz, D; Marget, M; Coggin J, Jr; Barsoum, A; Rohrer, J; Schmitz, N; Zeis, M (2003-12-15). "Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies". Blood. 102 (13): 4416–23. doi:10.1182/blood-2003-01-0198. PMID 12869512. S2CID 9814435.

[4] Siegel, S; Wagner, A; Schmitz, N; Zeis, M (2003). "Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model". British Journal of Haematology. 122 (6): 911–4. doi:10.1046/j.1365-2141.2003.04535.x. PMID 12956760.